MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting?
{{output}}
Osimertinib is the current first-line treatment for EGFR-mutated NSCLC, however, patients frequently relapse due to acquired resistance mutations. Amivantamab is a bispecific antibody against EGFR and MET alterations. Lazertinib is a tyrosine kinase inhibitor ... ...
